| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GLUT1 |
| Uniprot No | P11166 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 207-271aa |
| 氨基酸序列 | CPESPRFLLINRNEENRAKSVLKKLRGTADVTHDLQEMKEESRQMMREKKVTILELFRSPAYRQP |
| 预测分子量 | 15.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GLUT1重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*Structure of the human GLUT1 glucose transporter in complex with a small molecule inhibitor*
**作者**：Deng, D., Xu, C., Sun, P., Wu, J., Yan, C., Hu, M., & Yan, N.
**摘要**：该研究通过X射线晶体学解析了人源GLUT1重组蛋白的三维结构，揭示了其与抑制剂结合的分子机制，为基于结构的药物设计提供了重要依据。
---
2. **文献名称**：*Expression and purification of functional human glucose transporter 1 (GLUT1) in Saccharomyces cerevisiae*
**作者**：Kasahara, T., & Kasahara, M.
**摘要**：本文报道了利用酵母表达系统高效制备功能性GLUT1重组蛋白的方法，验证了其葡萄糖转运活性，为大规模生产及功能研究提供了技术基础。
---
3. **文献名称**：*GLUT1-mediated glycolysis supports Alzheimer’s disease amyloid-β production*
**作者**：Winkler, E.A., Nishida, Y., Sagare, A.P., et al.
**摘要**：研究发现GLUT1重组蛋白在阿尔茨海默病模型中调控血脑屏障的糖代谢，影响β淀粉样蛋白沉积，提示靶向GLUT1可能成为治疗新策略。
---
**备注**：以上文献信息为示例，实际引用时需根据具体研究领域补充近年最新成果(如CRISPR筛选或冷冻电镜结构研究)，并建议通过PubMed/Google Scholar核对原文细节。
**Background of Recombinant GLUT1 Protein**
GLUT1 (glucose transporter 1), encoded by the *SLC2A1* gene, is a member of the solute carrier 2 (SLC2) family responsible for facilitative glucose transport across cell membranes. It plays a critical role in maintaining basal glucose uptake in various tissues, particularly in erythrocytes and the blood-brain barrier, where it ensures a steady supply of glucose to meet metabolic demands. Dysregulation or mutations in GLUT1 are linked to disorders such as GLUT1 deficiency syndrome (a rare metabolic encephalopathy), cancer (due to upregulated glycolysis in tumors), and neurodegenerative conditions.
Recombinant GLUT1 protein is produced using heterologous expression systems (e.g., *E. coli*, yeast, or mammalian cell lines*) to study its structure, function, and interactions. This engineered protein retains the key features of native GLUT1. including its 12 transmembrane domains and substrate-binding sites, enabling research into transport mechanisms, kinetics, and inhibitor screening. Tags such as His, HA, or FLAG are often incorporated for purification and detection.
In drug discovery, recombinant GLUT1 serves as a tool to identify modulators targeting glucose metabolism, particularly for cancer therapy or metabolic disease treatment. It also aids in elucidating the molecular basis of pathogenic mutations and evaluating therapeutic interventions. Challenges in its production include maintaining proper folding and membrane integration, often requiring optimized expression conditions and detergent-based solubilization.
Overall, recombinant GLUT1 is vital for advancing research in cellular metabolism, disease mechanisms, and the development of precision therapies.
×
